Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Squamous Cell Carcinoma of Head and Neck 5Skin Neoplasms 5Neoplasm Metastasis 5Melanoma 5Lung Neoplasms 5Carcinoma 5Recurrence 4Neoplasms 4Mouth Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Adenocarcinoma 3Ovarian Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Laryngeal Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Squamous Cell 2Vaccinia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumors 1

Interventions

Magnetic Resonance Spectroscopy 8X-Rays 6Specimen Handling 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 5Biopsy 4ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2lutetium Lu 177 dotatate 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2LY3023414 2pembrolizumab 1neratinib 1cemiplimab 1brigatinib 1Watchful Waiting 1Vincristine 1Vemurafenib 1Temozolomide 1Radiotherapy, Conformal 1Radiotherapy 1Radiation 1Platinum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ependymoma × cemiplimab × 90 days × Clear all
NCT07567469 2026-05-05

A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma

Regeneron Pharmaceuticals

Phase 1/2 Not yet recruiting
120 enrolled
CNS

Ependymoma, Glioma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡